Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study

Yu, Tianhua; Chen, Xin; Zhang, Xuanhe; Zhang, Er-Chi; Sun, Caixia

doi:10.1038/s41598-021-83149-5

Cited by 31 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early detection of ICC by screening is of vital importance in potential population with risk factors. Tumor size, R0 resection, lymph node metastasis, differentiation, adjuvant chemotherapy, CA19-9, T stage, PVTT, HBV infection/vaccination, and Eastern Cooperative Oncology Group performance status (ECOG-PS) have been reported as prognostic factors influencing survival outcomes of ICC in recent researches [ 2 , 31 , 37 , 40 , 56 – 58 ]. We identified NAR, tumor size >5 cm, multiple tumors, and poor differentiation as independent risk factors for OS in ICC patients undergoing hepatectomy.…”

Section: Discussionmentioning

confidence: 99%

Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort

Wang

Ciren

Danzeng

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. Intrahepatic cholangiocarcinoma (ICC) is the second most common liver malignancy after hepatocellular carcinoma (HCC), with a dismal prognosis and high heterogeneity. The oncological advantages of anatomical resection (AR) and nonanatomical resection (NAR) in HCC have been studied, but surgical strategies for ICC remain controversial with insufficient investigations. Materials and Methods. From Jan 2013 to Dec 2016, 3880 consecutive patients were retrospectively reviewed from a single center. Patients with ICC undergoing AR or NAR have been enrolled according to inclusion and exclusion criteria. Propensity score matching (PSM) analysis was performed between two groups with a 1 : 1 ratio. The primary endpoint was overall survival (OS), and the secondary endpoints included disease-free survival (DFS), intraoperative patterns, postoperative morbidity, mortality, complications and recurrence. A prognostic nomogram was developed by a multivariate Cox proportion hazard model. Results. After PSM, 99 paired cases were selected from 276 patients enrolled in this study. Patients in the AR group achieved better 1-, 3-, and 5-year OS (70%, 46%, and 34%, respectively) and DFS (61%, 21%, and 10%, respectively) than patients in the NAR group with statistical significance after PSM analysis. The postoperative complications and recurrence patterns were comparable between the two groups. Multivariate analysis identified NAR, tumor size >5 cm, multiple tumors, and poor differentiation as independent risk factors for OS ( p < 0.05 ). Selected patients can benefit most from AR, according to subgroup analysis. A prognostic nomogram based on six independent risk factors for OS and factors with clinical significance was constructed to predict OS in ICC patients. Conclusion. AR improved the long-term survival of ICC with comparable postoperative complications and similar recurrence patterns. AR is suggested in ICC patients with sufficient remnant liver volume. In addition to surgery strategy, malignant characteristics of tumors are risk factors for ICC prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort

Wang

Ciren

Danzeng

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…ICC is a malignant tumor derived from the bile duct epithelium and ranks second among the primary liver cancers. 1 , 18 The difference between ICC and extrahepatic cholangiocarcinoma is that ICC occurs in the liver parenchyma. Although the incidence of ICC worldwide is much lower than that of hepatocellular carcinoma (HCC), some recent studies have shown that the incidence of ICC has increased rapidly in the past few decades, and the mortality rate is still high.…”

Section: Discussionmentioning

confidence: 99%

“…Intrahepatic cholangiocarcinoma (ICC) is a very aggressive malignant tumor of the biliary tract, which is often diagnosed in the advanced stage. 1 – 2 Surgery is the main curative option. First-line chemotherapy is the preferred strategy in cases with macroscopic residual disease after surgery or locally recurrent or unresectable cholangiocarcinoma at the time of diagnosis.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-7-5p Inhibits Migration, Invasion and Metastasis of Intrahepatic Cholangiocarcinoma by Inhibiting MyD88

Tang¹,

Zhong²,

Yang³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Background and Aims: Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor derived from intrahepatic bile duct epithelial cells. Accumulating studies report that mi-croRNAs are widely involved in tumor migration and metastasis by regulation of target genes. miR-7-5p has been confirmed to inhibit tumor metastasis and to be related to prognosis for several malignant tumors. Our study investigated the underlying functions of miR-7-5p in ICC. Methods: The expression of miR-7-5p in ICC tissues but also in ICC cell lines was analyzed by real-time PCR. By analyzing the relationship between the clinicopathological parameters of 60 ICC patients and the expression level of miR-7-5p, the effect of miR-7-5p on the prognosis was clarified. After transfected with miR-7-5p mimics or miR-7-5p inhibitor, cell counting kit-8 assay was applied to evaluate the cells proliferation, flow cytometry was applied to analyze the cells apoptosis, wound healing assay and transwell chamber assay were applied to analyze the cell invasion and migration. A luciferase reporter assay was identified the relationship of miR-7-5p and myeloid differentiation factor 88 (MyD88). Western blotting was used to analyze the proteins expression. And immunochemistry was performed to determine the expression of MYD88 in ICC tissues. Results: Our data showed the expression of miR-7-5p was down-regulated not only in ICC tissues but also in ICC cell lines compared with normal controls. Low expression of miR-7-5p was notably associated with poor prognosis in ICC patients. miR-7-5p negatively regulated cell proliferation, migration, invasion and apoptosis in ICC cells. We further verified that MyD88 was a novel target of miR-7-5p and was significantly overexpressed in ICC tissues. Overexpression of MyD88 counteracted the effects of miR-7-5p in ICC cells. Conclusions: The present findings suggest that miR-7-5p plays a pivotal role in ICC invasion by regulating MyD88. Ampliative insight into the key factors of ICC invasion may result in the development of new treatment options for ICC.

show abstract

“…Nonetheless, the vast majority of CCA occurs sporadically, without the presence of an underlying disease [ 10 , 13 ]. Merely a few prognostic factors have been investigated in recent years, including tumor size, surgery, pathological grade or Union for International Cancer Control (UICC) stage [ 14 ]. The role of liver fibrosis as a prognostic marker for survival is still controversially discussed [ 15 , 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy

Kinzler

Klasen

Schulze

et al. 2022

JCM

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (iCCA) is the most frequent subtype of cholangiocarcinoma (CCA), and the incidence has globally increased in recent years. In contrast to surgically treated iCCA, data on the impact of fibrosis on survival in patients undergoing palliative chemotherapy are missing. We retrospectively analyzed the cases of 70 patients diagnosed with iCCA between 2007 and 2020 in our tertiary hospital. Histopathological assessment of fibrosis was performed by an expert hepatobiliary pathologist. Additionally, the fibrosis-4 score (FIB-4) was calculated as a non-invasive surrogate marker for liver fibrosis. For overall survival (OS) and progression-free survival (PFS), Kaplan–Meier curves and Cox-regression analyses were performed. Subgroup analyses revealed a median OS of 21 months (95% CI = 16.7–25.2 months) and 16 months (95% CI = 7.6–24.4 months) for low and high fibrosis, respectively (p = 0.152). In non-cirrhotic patients, the median OS was 21.8 months (95% CI = 17.1–26.4 months), compared with 9.5 months (95% CI = 4.6–14.3 months) in cirrhotic patients (p = 0.007). In conclusion, patients with iCCA and cirrhosis receiving palliative chemotherapy have decreased OS rates, while fibrosis has no significant impact on OS or PFS. These patients should not be prevented from state-of-the-art first-line chemotherapy.

show abstract

Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study

Cited by 31 publications

References 35 publications

Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort

Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort

MicroRNA-7-5p Inhibits Migration, Invasion and Metastasis of Intrahepatic Cholangiocarcinoma by Inhibiting MyD88

Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy

Contact Info

Product

Resources

About